Mozart Therapeutics shares trial results for MTX-101, a unique dual-action CD8 Treg adjuster used for treating autoimmune diseases, at the 2023 American College of Rheumatology Convergence.
SCG Cell Therapy reports that SCG101 enhances tumor reactions and maintains consistent antiviral actions in patients having advanced hepatocellular carcinoma linked to HBV.
BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC).
The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.
NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.
Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.